4.4 Review

Quantitative 201thallium scintigraphy for prediction of histological response to neoadjuvant chemotherapy in osteosarcoma; systematic review and meta-analysis

Journal

SURGICAL ONCOLOGY-OXFORD
Volume 24, Issue 3, Pages 194-199

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.suronc.2015.06.009

Keywords

meta-analysis; Thallium scintigraphy; Osteosarcoma; Chemotherapy response

Ask authors/readers for more resources

Purpose: The histological assessment of tumor necrosis of the excised lesion after neoadjuvant chemotherapy is the most important prognostic factor for patients with osteosarcoma, but more early prognostic factors are needed for the adjustment of adjuvant treatment regimen. The objective of this systematic review is to provide an up-to-date and unprecedented summary of the value of (201)thallium (Tl-201) scintigraphy for the preoperative evaluation of the chemotherapy response of osteosarcoma. Methods: Studies evaluating Tl-201 scintigraphy for the preoperative evaluation of the chemotherapy response of osteosarcoma were systematically searched for in MEDLINE, EMBASE, and Web of Science. Pooled sensitivity and specificity for each study were calculated into 2 x 2 contingency tables. The DerSimonian-Laird random-effects method was used for determining the pooled diagnostic odds ratio and the area under curve (AUC) of the summary receiver operating characteristic (SROC) curve. Results: A total of six studies with 139 patients who fulfilled all of the inclusion criteria were considered for the meta-analysis. The pooled sensitivity and specificity were 0.93 (95% CI, 0.83-0.98) and 0.63 (95% CI, 0.52-0.74), respectively. A significant difference was found between the good and poor responders in the diagnostic odds ratio. The SROC curve showed that the AUC was 0.840, indicating excellent diagnostic accuracy. There was no statistically significant heterogeneity among the six studies. Conclusions: The alteration ratio derived from Tl-201 scintigraphy was useful for evaluating the histological response of patients to neoadjuvant chemotherapy in osteosarcoma. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available